Clinical impact of guideline-based practice and patients’ adherence in uncontrolled hypertension

Clinical Hypertension

Table 4 Patients-reported outcomes according to the status on GBP and medication adherence at 6 months

Variable	GBP				Non-GBP (n = 182)		Total (n = 502)		P-value^*
	Adherence (n = 142)		Non-adherence (n = 146)		Non-GBP (n = 182)		Total (n = 502)
	n	Mean ± SD	n	Mean ± SD	n	Mean ± SD	n	Mean ± SD
TSQM domains
Effectiveness	141	66.5 ± 12.0^b	146	62.4 ± 13.5^c	181	61.4 ± 12.7^c	500	63.2 ± 12.8	0.001
Side effects	140	99.5 ± 4.2^b	146	97.6 ± 10.4^c	181	99.2 ± 5.9^b	499	98.8 ± 7.2	0.048
Convenience	141	72.1 ± 10.1^b	146	64.1 ± 12.7^c	181	65.4 ± 11.7^c	500	66.9 ± 12.0	< 0.001
Global satisfaction	141	65.7 ± 12.1^b	146	60.5 ± 14.2^c	181	59.2 ± 13.7^c	500	61.2 ± 13.7	< 0.001
EQ-VAS	140	77.6 ± 11.7^b	146	73.8 ± 14.7^c	181	74.4 ± 13.1^b,c	499	74.8 ± 13.7	0.030

GBP guideline-based practice, TSQM Treatment Satisfaction Questionnaire for Medication, EQ-VAS EuroQoL-visual analog scale
^*All P-values among three comparing groups by ANOVA
^{b, c}There is a significant difference between b and c by a post hoc Tukey’s test
Among the total number of patients in each group, those with no data on TSQM or EQ-VAS were excluded in the analysis

ISSN: 2056-5909